Sempra Seen As A Top Pick In Electricity
RBC Capital Markets reiterated a $55 target price on the energy provider.
From ]]>”>Forbes Market Updates
Archive for March, 2006
ViroPharma’s Phase II Data ‘Introduces Some Uncertainty’
Piper Jaffray maintained a “market perform” rating on the drugmaker.
From ]]>”>Forbes Market Updates
EMC Well-Positioned To Capitalize On Robust Demand
Banc of America Securities reiterated a “buy” rating on the information infrastructure company.
From ]]>”>Forbes Market Updates
ATI’s Challenges Persist
Caris & Co. reiterated an “average” rating on the semiconductor company.
From ]]>”>Forbes Market Updates
Tech Sector Faces Many Drivers And Challenges
Cowen & Co. said it remained conflicted in its approach to technology stocks.
From ]]>”>Forbes Market Updates
Biogen Idec Faces Long-Term Growth Challenges
Morgan Stanley expressed caution regarding the biotechnology firm’s long-term outlook.
From ]]>”>Forbes Market Updates
